Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2020-12-07 11:00:14
Oslo, Norway, 7 December 2020<br />
<br />
Nordic Nanovector ASA (OSE: NANOV) announces that its Interim CEO, Dr Lars
Nieba<br />
will present a corporate overview via live webcast at DNB's 11[th] Annual
Nordic<br />
Healthcare Conference, taking place on 15 December 2020.<br />
<br />
Presentations details are as follows:<br />
<br />
DNB's 11[th] Annual Nordic Healthcare Conference<br />
Date: 15 December 2020<br />
Time: 09:50 to 10:10 (CET)<br />
<br />
The presentation will be available at the same time at
www.nordicnanovector.com<br />
in the section: Investors & Media/Reports and Presentation/Presentations.<br />
<br />
For further information, please contact:<br />
<br />
IR enquiries<br />
<br />
Malene Brondberg, CFO<br />
Cell: +44 7561 431 762<br />
Email: ir@nordicnanovector.com<br />
<br />
Media Enquiries<br />
<br />
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)<br />
Tel: +44 203 926 8535<br />
Email: nordicnanovector@citigatedewerogerson.com<br />
<br />
About Nordic Nanovector:<br />
<br />
Nordic Nanovector is committed to develop and deliver innovative therapies to<br
/>
patients to address major unmet medical needs and advance cancer care. The<br />
Company aspires to become a leader in the development of targeted therapies
for<br />
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is<br
/>
Betalutin[®], a novel CD37-targeting radioimmunotherapy designed to advance
the<br />
treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial<br />
unmet medical need, representing a growing market forecast to be worth nearly<br
/>
USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to<br
/>
Betalutin[®] and intends to actively participate in the commercialisation of<br
/>
Betalutin[®] in the US and other major markets.<br />
<br />
Further information can be found at www.nordicnanovector.com.<br />
<br />
This information is subject to a duty of disclosure pursuant to Sections 4-2
and<br />
5-12 of the Securities Trading Act.